U.S. NEUROPATHIC PAIN TREATMENT MARKET ANALYSIS

U.S. Neuropathic Pain Treatment Market, by Drug Type (Pain Relievers (NSAIDS, Opioids (Tramadol, Oxycodone, and Others)), Anti-seizure Medications (Gabapentin, Pregabalin, and Others), Topical Treatments, Antidepressants (Duloxetine, Amitriptyline, Escitalopram, and Others), and Others), by Indication (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Dec 2022
Code : CMI5429
Pages :155
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Companies covered:

Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson & Johnson, Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., Cipla Inc., Lupin Limited, Averitas Pharma, Inc., NeuroBo Pharmaceuticals, Inc., LEXICON PHARMACEUTICALS, INC., Asahi Kasei Corporation, Vertex Pharmaceuticals Incorporated, and Biogen

U.S. Neuropathic Pain Treatment Market – Competitive Landscape

Major players operating in the U.S. neuropathic pain treatment market include Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson & Johnson, Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., Cipla Inc., Lupin Limited, Averitas Pharma, Inc., NeuroBo Pharmaceuticals, Inc., LEXICON PHARMACEUTICALS, INC., Asahi Kasei Corporation, Vertex Pharmaceuticals Incorporated, and Biogen

U.S. Neuropathic Pain Treatment Market Report Snapshots